AARON
An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
| Studienleiter | Prof. Dr. Marion Subklewe |
|---|---|
| EudraCT-Nr. | 2018-002939-21 |
| Studientyp | Phase II |
| Indikation | AML |
| ClinicalTrial | NCT04913922 |